Promising, especially for people with LBD mutation: NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

[Maxone73]

"In phase I, 20 out of the total 47 patients had AR LBD mutation. In phase IIa, all 45 patients had AR LBD mutation. A decrease in PSA (prostate-specific antigen) levels of 50% or more occurred in 14/19 (73.7%) patients with AR LBD mutation and 2/23 (8.7%) AR-wild-type patients in phase I, and in 24/45 (53.3%) patients with AR LBD mutation in phase IIa. Median circulating testosterone levels declined from 3.0 ng/dl at baseline to undetectable levels within the first week of ODM-208 treatment in 46/53 (87%) patients."

biospace.com/article/releas...

[j-o-h-n]

I have a feeling that when you were 3 years old, your dear Mom had them vaccinate you with a research phonograph needle......

youtube.com/watch?v=8UmM95w...(Not working as expected?)

Good Luck, Good Health and Good Humor.

j-o-h-n Friday 12/29/2023 5:51 PM EST

[CAMPSOUPS]

I've mentioned I was on this trial for about 5 months. My PC very slowly progressed but I felt great. The trial for me was also a bridge until Pluvicto became available again.

I think ODM-208 has promise. I think of it as a super Zytiga.

"ODM-208 is a novel selective inhibitor of an enzyme called CYP11A1 ( Cytochrome P450 cholesterol side-chain cleavage enzyme). This results in blocking of the first step of the steroid production pathway in which cholesterol is converted to several hormones in the body (androgens, glucocorticoids and mineralocorticoids). ODM-208 decreases the male sex hormones in the body when other drugs are no longer able to have this effect. Because ODM-208 decreases also the levels of corticosteroid hormones which are essential for vital functions ODM-208 is combined with dexamethasone and fludrocortisone."

[Maxone73 in reply to CAMPSOUPS]

This is great news! It's always good to have first hand impressions!